Anchor Therapeutics is pre-clinical stage drug discovery and development company. We are developing first-in-class pharmaceutical candidates, called pepducins, to address several therapeutic areas including cancer, inflammation, metabolism, heart disease and pain. Pepducins are allosteric modulators of G protein coupled receptors (GPCRs). These lipopeptide molecules may treat the underlying cause of the disease because they are designed to specifically target an intracellular domain of a GPCR to affect internal cell signaling. Anchor has achieved in vivo efficacy in multiple preclinical programs in our portfolio and is preparing to bring the first pepducin drug candidate into clinical trials. We are also actively seeking collaborations to advance some of our pepducin pharmaceutical candidates into clinical trials, or to identify new clinical development candidates that act on targets nominated by our partners.

Anchor is an experienced team of scientists and professionals driving an expansive discovery platform protected by a broad patent estate. Our pepducin technology was invented at Tufts New England Medical Center by founders Drs. Athan Kuliopulos and Lidija Covic. Their remarkable discovery that lipidated fragments of intracellular GPCR loops could modulate GPCR action in targeted cell-signaling pathways was subsequently validated in multiple in vivo disease models. Pepducin technology has been the subject of numerous peer-reviewed publications in journals such as Nature Medicine, Circulation, Journal of Biological Chemistry and Proceedings of the National Academy of Sciences. Anchor has exclusive worldwide license to pepducin technology from Tufts and has augmented its intellectual property position through the prosecution of over 30 worldwide patent applications surrounding the pepducin approach.